BE892357A - Nouveaux derives de l'erythromycine a, procede pour leur preparation et leur utilisation comme substances anti-bacteriennes - Google Patents

Nouveaux derives de l'erythromycine a, procede pour leur preparation et leur utilisation comme substances anti-bacteriennes

Info

Publication number
BE892357A
BE892357A BE0/207464A BE207464A BE892357A BE 892357 A BE892357 A BE 892357A BE 0/207464 A BE0/207464 A BE 0/207464A BE 207464 A BE207464 A BE 207464A BE 892357 A BE892357 A BE 892357A
Authority
BE
Belgium
Prior art keywords
derivatives
preparation
bacterial substances
novel erythromycin
erythromycin
Prior art date
Application number
BE0/207464A
Other languages
English (en)
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25550598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE892357(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of BE892357A publication Critical patent/BE892357A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BE0/207464A 1981-03-06 1982-03-04 Nouveaux derives de l'erythromycine a, procede pour leur preparation et leur utilisation comme substances anti-bacteriennes BE892357A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
YU592/81A YU43006B (en) 1981-03-06 1981-03-06 Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof

Publications (1)

Publication Number Publication Date
BE892357A true BE892357A (fr) 1982-07-01

Family

ID=25550598

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/207464A BE892357A (fr) 1981-03-06 1982-03-04 Nouveaux derives de l'erythromycine a, procede pour leur preparation et leur utilisation comme substances anti-bacteriennes

Country Status (19)

Country Link
US (1) US4517359A (fr)
JP (1) JPS5858357B2 (fr)
AT (1) AT375945B (fr)
BE (1) BE892357A (fr)
CA (1) CA1191843A (fr)
CH (1) CH655728A5 (fr)
CZ (1) CZ418991A3 (fr)
DD (1) DD202437A5 (fr)
DE (1) DE3140449C2 (fr)
FR (1) FR2501212B1 (fr)
GB (1) GB2094293B (fr)
HU (1) HU186845B (fr)
IT (1) IT1200960B (fr)
PL (2) PL133764B1 (fr)
SE (1) SE457084B (fr)
SI (1) SI8110592A8 (fr)
SK (1) SK418991A3 (fr)
SU (1) SU1287755A3 (fr)
YU (1) YU43006B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464527A (en) * 1983-06-30 1984-08-07 Pfizer Inc. Antibacterial 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin A derivatives and intermediates therefore
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
WO1999020639A3 (fr) * 1997-10-16 1999-07-08 Pliva Pharm & Chem Works NOUVEAUX 3,6-HEMICETALS APPARTENANT A LA CLASSE DES 9a-AZALIDES
BG64600B1 (bg) * 1998-04-06 2005-08-31 Pliva, Farmaceutska Industrija, Dionicko Drustvo Кетолиди от класа на 15-членни лактами с антибактериална активност
US7419961B2 (en) 2002-10-29 2008-09-02 Zambon S.P.A. 9a-azalides with anti-inflammatory activity
US9700564B2 (en) 2009-09-04 2017-07-11 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US9717738B2 (en) 2008-10-07 2017-08-01 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
US10987357B2 (en) 2005-05-18 2021-04-27 Horizon Orphan, LLC Aerosolized fluoroquinolones and uses thereof
WO2021209563A1 (fr) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA835204B (en) * 1982-07-19 1985-02-27 Pfizer N-methyl 11-aza-10-deoxo-10-dihydroerythromycin a,intermediates therefor and processes for their preparation
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4526889A (en) * 1982-11-15 1985-07-02 Pfizer Inc. Epimeric azahomoerythromycin A derivative, intermediates and method of use
US4492688A (en) * 1983-11-25 1985-01-08 Pfizer Inc. Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin A and intermediates therefor
JPS59225198A (ja) * 1983-05-23 1984-12-18 フアイザ−・インコ−ポレ−テツド 抗菌性を有する9―デオキソ―9a―アザ―9a―ホモエリスロマイシンA,その製造方法および組成物
DE3461803D1 (en) * 1983-05-23 1987-02-05 Pfizer Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin a and intermediates therefor
GR80277B (en) * 1983-09-06 1985-01-04 Pfizer Azahomoerythromycin b derivatives and intermediates therefor
US4465674A (en) * 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor
US4518590A (en) * 1984-04-13 1985-05-21 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
US4921947A (en) * 1986-03-31 1990-05-01 Eli Lilly And Company Process for preparing macrolide derivatives
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (fr) * 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
US6017894A (en) * 1988-08-03 2000-01-25 Schering Corporation Actinomadura fulva subsp uruguayensis and antimicrobial complex and antimicrobial compounds isolated therefrom
YU45590A (sh) * 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
US5912331A (en) * 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5189159A (en) * 1992-04-02 1993-02-23 Merck & Co., Inc. 8a-AZA-8a-homoerythromycin cyclic iminoethers
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
TW271400B (fr) * 1992-07-30 1996-03-01 Pfizer
US5210235A (en) * 1992-08-26 1993-05-11 Merck & Co., Inc. Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics
US5332807A (en) * 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
DK0699207T3 (da) * 1993-05-19 1997-12-08 Pfizer Mellemprodukt til azithromycin
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
WO1995028939A1 (fr) * 1994-04-26 1995-11-02 Nobuhiro Narita Composition medicinale servant de medicament contre le cancer bronchopulmonaire 'non a petites cellules'
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ES2163504T5 (es) * 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
ES2122905B1 (es) * 1996-07-11 1999-11-16 Astur Pharma Sa Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato).
PT102006B (pt) * 1997-05-19 2000-06-30 Hovione Sociedade Quimica S A Novo processo de preparacao de azitromicina
HN1998000074A (es) * 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JP2003512290A (ja) * 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての8a−アザライド
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
TW546302B (en) 1998-05-08 2003-08-11 Biochemie Sa Improvements in macrolide production
EP1437360A3 (fr) * 1998-08-19 2005-04-06 Pfizer Products Inc. C11-carbamates des macrolides antibactériens
US6043227A (en) * 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
CA2245398C (fr) * 1998-08-21 2002-01-29 Apotex Inc. Clathrate d'isopropanol monohydrate d'azithromycine et methodes d'obtention
ES2243066T3 (es) 1998-09-22 2005-11-16 Pfizer Products Inc. Antibioticos de carbamato y carbazato cetolida.
ID28286A (id) * 1998-11-03 2001-05-10 Pfizer Prod Inc Antibiotik-antibiotik makrolida baru
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків
SI20639A (sl) 1998-11-30 2002-02-28 Teva Pharmaceutical Industries Ltd. Etanolat azitromicina, postopek za njegovo pripravo in njegovi farmacevtski sestavki
AU6484199A (en) 1998-12-10 2000-06-26 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
TR200102128T2 (tr) * 1999-01-27 2001-12-21 Pfizer Products Inc. Ketolid antibiyotikler
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
CA2373117C (fr) * 1999-05-24 2006-02-28 Pfizer Products Inc. Derives de 13-methyl-erythromycine
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6764996B1 (en) 1999-08-24 2004-07-20 Abbott Laboratories 9a-azalides with antibacterial activity
EP1101769A3 (fr) 1999-11-18 2001-10-24 Pfizer Products Inc. Dérivés de l'érythromycine contenant de l'azote
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CA2396426A1 (fr) * 2000-01-04 2001-07-12 Teva Pharmaceutical Industries Ltd. Procede de preparation d'azithromycine dihydratee
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
DE10030781A1 (de) * 2000-06-29 2002-01-17 Hassan Jomaa Kombinationspräparate von 3-N-Formylhydroxylaminopropylphosphonsäurederivaten oder 3-N-Acetylhydroxylaminopropylphosphonsäurederivaten mit spezielen pharmazeutischen Wirkstoffen
US6403776B1 (en) 2000-07-05 2002-06-11 Pfizer Inc. Synthesis of carbamate ketolide antibiotics
ES2260047T3 (es) 2000-07-25 2006-11-01 Laboratorio Silanes, S.A. De C.V. Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
WO2002015842A2 (fr) * 2000-08-23 2002-02-28 Wockhardt Limited Procede de preparation d'azithromycine anhydre
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
HU229488B1 (hu) 2000-11-27 2014-01-28 Sandoz Ag Eljárás makrolid hidrátok elõállítására
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
IL158059A0 (en) 2001-04-27 2004-03-28 Pfizer Prod Inc Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
EP1671978A1 (fr) 2001-05-22 2006-06-21 Pfizer Products Inc. Nouvelle forme cristalline de l'azithromycine
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE60209704T2 (de) * 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
GEP20063812B (en) * 2001-08-21 2006-05-10 Pfizer Prod Inc Single dose azithromycin for treating respirator infections
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
US6764997B2 (en) * 2001-10-18 2004-07-20 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
US7182915B2 (en) * 2001-11-30 2007-02-27 Bristol-Myers Squibb Company Pipette configurations and arrays thereof for measuring cellular electrical properties
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US20050171342A1 (en) * 2002-02-15 2005-08-04 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2003070254A1 (fr) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugues antibiotiques
EP1483579A4 (fr) * 2002-02-15 2006-07-12 Merckle Gmbh Conjugues de composes biologiquement actifs, methodes de preparation et d'utilisation des conjugues, formulation et applications pharmaceutiques obtenues a partir desdits conjugues
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
JPWO2003072589A1 (ja) * 2002-02-26 2005-06-16 明治製菓株式会社 新規15員環アザライド及び新規16員環ジアザライド誘導体とその製造法
ITMI20021209A1 (it) * 2002-06-04 2003-12-04 Chemi Spa Processo di preparazione di azitromicina ad elevata purezza
AU2003245504A1 (en) * 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US6855813B2 (en) * 2002-07-19 2005-02-15 Alembic Limited Process for the preparation of azithromycin monohydrate
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004087729A1 (fr) * 2003-03-25 2004-10-14 Teva Pharmaceutical Industries Ltd. Produits de degradation de l'azithromycine, et methodes permettant de les identifier
US6645941B1 (en) * 2003-03-26 2003-11-11 Enanta Pharmaceuticals, Inc. 6,11-3C-bicyclic 9a-azalide derivatives
ES2220229B1 (es) * 2003-05-29 2005-10-16 Quimica Sintetica, S.A. Sales de adicion de azitromicina y acido citrico y procedimiento para su obtencion.
EP2529730A1 (fr) * 2003-06-16 2012-12-05 ANDRX Pharmaceuticals LLC. Composition à libération prolongée orale
GB2395482A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Process for preparing non-hygroscopic azithromycin dihydrate
US8425936B2 (en) 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535177A1 (fr) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Pastille robuste
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005019238A1 (fr) * 2003-08-22 2005-03-03 Meiji Seika Kaisha, Ltd. Nouveaux derives d'azalide et d'azalactam et procede permettant de produire ces derives
WO2005023184A2 (fr) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Produit antibiotique, son utilisation et sa formulation
CA2538064C (fr) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotique, son utilisation et sa formulation
US7276487B2 (en) * 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
WO2005053652A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
CA2547239A1 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes posologiques multiparticulaires d'azithromycine obtenues par des procedes se deroulant en milieu liquide
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
DE602004014805D1 (de) * 2003-12-04 2008-08-14 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
WO2006011160A1 (fr) * 2004-06-28 2006-02-02 Alembic Limited Procede pour la preparation de clathrate d'isopropanol d'azithromycine monohydrate
EP1771158A4 (fr) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Comprimé pour distribution par impulsion
WO2006004085A1 (fr) * 2004-07-02 2006-01-12 Wakamoto Pharmaceutical Co., Ltd. Composition médicinale à base d'eau contenant de l'azithromycine et procédé servant à préparer celle-ci
US7683162B2 (en) * 2004-08-30 2010-03-23 Taro Pharmaceutical Industries Limited Process of preparing a crystalline azithromycin monohydrate
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
BRPI0519135A2 (pt) * 2004-12-21 2008-12-23 Pfizer Prod Inc macrolÍdeos
CN101228171A (zh) * 2005-07-26 2008-07-23 默克勒有限公司 作为5-脂氧化酶和环加氧酶抑制剂的吡咯里嗪和中氮茚化合物的大环内酯偶联物
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
JP5015016B2 (ja) * 2006-02-07 2012-08-29 大正製薬株式会社 10a−アザライド化合物
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2010501541A (ja) 2006-08-24 2010-01-21 ウォックハート リサーチ センター 抗菌活性を有する新規マクロライド及びケトライド
US7704959B2 (en) 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
US8293715B2 (en) * 2007-08-06 2012-10-23 Taisho Pharmaceutical Co., Ltd. 10a-Azalide compound crosslinked at 10a- and 12-positions
US20090062220A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched azithromycin
US8299035B2 (en) * 2008-05-15 2012-10-30 Taisho Pharmaceutucal Co., Ltd. 10a-azalide compound having 4-membered ring structure
EP2346509B1 (fr) 2008-10-07 2020-05-13 Horizon Orphan LLC Inhalation de lévofloxacine pour réduire une inflammation des poumons
US20170128481A9 (en) 2009-03-06 2017-05-11 Insite Vision Corporation Ocular treatment with reduced intraocular pressure
WO2011015219A1 (fr) 2009-08-06 2011-02-10 Shifa Pharmed Industrial Group Co. Procédé de purification d'azithromycine par séparation de ses produits de dégradation thermiques et/ou isomères
JP5851516B2 (ja) 2010-12-09 2016-02-03 ウォックハート リミテッド ケトライド化合物
AR085286A1 (es) 2011-02-21 2013-09-18 Taisho Pharmaceutical Co Ltd Derivado de macrolido sustituido en la posicion c-4
JP5718488B2 (ja) 2011-03-01 2015-05-13 ウォックハート リミテッド ケトライド中間体の調製方法
EP2688900B1 (fr) 2011-03-22 2016-09-28 Wockhardt Limited Procédé de préparation de composés de cétolides
WO2013088274A1 (fr) 2011-12-14 2013-06-20 Wockhardt Limited Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
MX2015008146A (es) 2012-12-24 2016-01-20 Univ Ramot Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas.
US9044508B2 (en) 2013-03-15 2015-06-02 Insite Vision Corporation Concentrated aqueous azalide formulations
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
AR102810A1 (es) 2014-08-18 2017-03-29 Taisho Pharmaceutical Co Ltd Derivado de macrólido sustituido en la posición c-4
CN104910222B (zh) * 2015-06-29 2018-02-13 石药集团欧意药业有限公司 阿奇霉素新晶型化合物及其制备方法
CN105061528B (zh) * 2015-08-05 2017-10-17 浙江维康药业股份有限公司 一种阿奇霉素化合物及含有该化合物的阿奇霉素软胶囊

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681326A (en) * 1971-01-11 1972-08-01 Abbott Lab 9-substituted erythromycin a and b oximes
YU43116B (en) * 1979-04-02 1989-04-30 Pliva Pharm & Chem Works Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
US4283527A (en) * 1980-04-01 1981-08-11 Pfizer Inc. Erythromycylamine 11,12-carbonate and derivatives thereof

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4464527A (en) * 1983-06-30 1984-08-07 Pfizer Inc. Antibacterial 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin A derivatives and intermediates therefore
WO1999020639A3 (fr) * 1997-10-16 1999-07-08 Pliva Pharm & Chem Works NOUVEAUX 3,6-HEMICETALS APPARTENANT A LA CLASSE DES 9a-AZALIDES
BG64600B1 (bg) * 1998-04-06 2005-08-31 Pliva, Farmaceutska Industrija, Dionicko Drustvo Кетолиди от класа на 15-членни лактами с антибактериална активност
US7419961B2 (en) 2002-10-29 2008-09-02 Zambon S.P.A. 9a-azalides with anti-inflammatory activity
US10987357B2 (en) 2005-05-18 2021-04-27 Horizon Orphan, LLC Aerosolized fluoroquinolones and uses thereof
US9717738B2 (en) 2008-10-07 2017-08-01 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
US10149854B2 (en) 2008-10-07 2018-12-11 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
US10722519B2 (en) 2008-10-07 2020-07-28 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
US9700564B2 (en) 2009-09-04 2017-07-11 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US10231975B2 (en) 2009-09-04 2019-03-19 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
WO2021209563A1 (fr) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire

Also Published As

Publication number Publication date
CA1191843A (fr) 1985-08-13
CZ418991A3 (en) 1993-01-13
PL235329A1 (fr) 1982-09-27
YU43006B (en) 1989-02-28
FR2501212A1 (fr) 1982-09-10
AT375945B (de) 1984-09-25
JPS57158798A (en) 1982-09-30
PL131784B1 (en) 1985-01-31
ATA440081A (de) 1984-02-15
SE457084B (sv) 1988-11-28
FR2501212B1 (fr) 1985-08-09
SU1287755A3 (ru) 1987-01-30
PL133764B1 (en) 1985-06-29
SK418991A3 (en) 1995-07-11
YU59281A (en) 1983-06-30
GB2094293A (en) 1982-09-15
IT1200960B (it) 1989-01-27
HU186845B (en) 1985-09-30
GB2094293B (en) 1985-12-18
US4517359A (en) 1985-05-14
DE3140449A1 (de) 1983-10-13
DD202437A5 (de) 1983-09-14
IT8267263A0 (it) 1982-03-05
JPS5858357B2 (ja) 1983-12-24
SI8110592A8 (en) 1996-06-30
SE8201311L (sv) 1982-09-07
CH655728A5 (de) 1986-05-15
DE3140449C2 (de) 1984-06-20

Similar Documents

Publication Publication Date Title
BE892357A (fr) Nouveaux derives de l'erythromycine a, procede pour leur preparation et leur utilisation comme substances anti-bacteriennes
MA19470A1 (fr) Nouveaux derives d'arylphenylethers utiles comme microbicides, procede pour leur preparation et leur utilisation
PT72331B (fr) Procede de preparation de nouvelles oximes derives de l'erythromycine a
FR2603586B1 (fr) Composes derives de l'imidazoquinolinylether, et leur procede de preparation
FR2603899B1 (fr) Procede perfectionne pour l'expression de recombinants
MA20938A1 (fr) Procede de preparation du besylate d'amlodipine.
MA22922A1 (fr) Procede pour la preparation de nouveaux composes .
MA21323A1 (fr) Dihydrate d'azithromycine et son procede de preparation.
FR2497664B1 (fr) Comprimes d'erythromycine base et leur procede de preparation
MA22955A1 (fr) Procede pour la preparation de nouveaux composes .
FR2509300B1 (fr) Derives d'azetidinone et procede pour leur preparation
RO79689A (fr) Procede continu pour l'obtention de l'o0yde d'ethylene
BE880153A (fr) Derives de 7-oxo-4-thia-1-aza-bicyclo- (3,2,0) -heptane, procede pour les preparer et leur application comme medicaments
FR2506772B1 (fr) Glycosides d'anthracycline, procede pour les preparer et leur usage comme medicament
FR2348223A1 (fr) Procede de preparation d'antibiotiques aminoglycosidiques
BE882067A (fr) Derives de l'acide d-2-hydroxy-4-methylmercaptobutyrique, procede pour leur preparation et utilisation de ces composes
BE888578A (fr) Composition de sec-butylbiphenyle et procede d'obtention,
FR2512820B1 (fr) Nouveaux derives de benzothiazoline utiles comme medicaments et procede pour leur preparation
FR2571052B1 (fr) Derives de 1,3-oxazolidine-2-one et leur procede de preparation
MA19177A1 (fr) Nouveaux derives de l'indene ,procedes pour leur preparation
MA18800A1 (fr) Naphtylamines acylees,procede pour leur preparation et leur application comme phytofongicides
FR2552433B1 (fr) Nouveaux derives de 1,3,4-thiadiazole, procede pour leur preparation et leur utilisation comme agents anti-ulcere
MA18891A1 (fr) Composes d'amino-thiadiazolyle,procede pour leur preparation
BE895213A (fr) Derives d'azolyl-pentene, leur procede de preparation et leur utilisation
FR2559771B1 (fr) Derives de la 3-pyrrolidinopropiophenone et procede pour leur preparation

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 094C0012

CCPV Grant of a supplementary protection certificate

Free format text: 094C0012, EXPIRES 20060404

RE20 Patent expired

Owner name: SOUR PLIVA FARMACEUTSKA KEMIJSKA PREHRAMBENA I KO

Effective date: 20020304

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME: AZITHROMYCINUM DIHYDRIC.(=AZITHROMYCINUM 250 MG); NAT REG.: 241 S 336 F 4 19940623; FIRST REG.: GB PL 0057/0335 19910404

Spc suppl protection certif: 94C0012

Filing date: 19940830

Expiry date: 20020304

Extension date: 20060404